Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
XtalPi unveiled its new AI-driven XGlue platform at the 2026 International Symposium on Molecular Glue Drug Discovery in Shanghai, aiming to accelerate systematic discovery of molecular glue therapeutics.
Nucs AI has established a Medical Advisory Board to guide the clinical integration of its AI-based imaging technology in cancer care. The board includes experts from institutions such as UCLA, AstraZeneca, and the European Institute of Oncology.
Healthcare Triangle, Inc. has entered a collaboration with Better.care to extend digital health and data platform services across Europe, Southeast Asia, the Middle East, and Africa. The agreement includes workforce enablement programs and positions Healthcare Triangle as a preferred service provider in multiple markets.
Viveka Health has achieved the HITRUST e1 Certification, confirming the effectiveness of its foundational cybersecurity controls. The certification process was conducted in collaboration with Palindrome Technologies, a HITRUST Authorized External Assessor.
EyeContactDX has named developmental-behavioral pediatrician Dr. Carol Weitzman as Senior Strategic Advisor to support the expansion of its AI-based eye-tracking autism screening tool in primary care.
EQT Life Sciences and Gimv have co-led a €51 million Series B funding round for Exciva to advance its lead candidate, Deraphan, into Phase 2 clinical trials targeting agitation in Alzheimer’s disease.
OpenAI has launched ChatGPT Health, a dedicated feature that allows users to discuss health and wellness topics in a secure environment. The new section separates health-related chats from other conversations and supports integrations with apps like Apple Health, Function, and MyFitnessPal.
iScribeHealth has been selected by Lifepoint Health to provide AI-powered scribing technology that captures and integrates clinical notes in real time, reducing documentation tasks for physicians.
SENA Health has reported a 300% year-over-year growth driven by increased adoption of its AI-powered Command Center, which streamlines patient access and administrative workflows for healthcare organizations.
CAQH announced that twelve major health plans have become its shareholders, a move aimed at strengthening partnerships and accelerating the development of connected healthcare data solutions.
Siemens CEO Roland Busch said the company is exploring potential acquisitions in artificial intelligence, life sciences, and operations software, building on its $5.1 billion purchase of Dotmatics last year to strengthen AI-driven drug development and data infrastructure.
Biobeat Technologies has raised $50 million in Series B funding led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical to expand commercialization of its FDA-cleared, cuff-less 24-hour ambulatory blood pressure monitoring system in the U.S.
Qualified Health has partnered with the University of Texas System to roll out a large-scale generative AI deployment across its health institutions, aiming to enhance care delivery, operations, and research.
Fountain Life announced outcomes showing measurable disease reversal across multiple health areas, supported by more than 15 billion clinical data points and its AI-powered platform ZORI.
AllOne Health has acquired Carebridge EAP, Comp EAP, and ERC EAP, marking its 18th, 19th, and 20th acquisitions since 2016 to strengthen its nationwide Employee Assistance Program services.
UbiSim has introduced AI Narrative Analysis, a new feature that helps nursing educators quickly assess simulation data and provide targeted feedback, reducing review time by up to 90%.
Caris Life Sciences has entered a multi-year collaboration and license agreement with Genentech to identify and validate new oncology targets in solid tumors. The agreement includes $25 million in upfront and near-term payments and up to $1.1 billion in potential milestone payments.
OpenAI-backed biotech firm Chai Discovery has raised $130 million in Series B funding at a $1.3 billion valuation, led by General Catalyst and Oak HC/FT. The company’s Chai-2 platform uses AI to design new antibodies from scratch, improving success rates in drug discovery.
The Michael J. Fox Foundation for Parkinson’s Research has begun funding its first target validation projects under the multi-year Targets to Therapies Initiative, focusing on biological targets such as NOD2, OGA, and TRPML1 to advance new Parkinson’s treatments.
ChemLex has raised $45 million and established its global headquarters and self-driving laboratory in Singapore to accelerate AI-driven chemical discovery for pharmaceuticals.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
